Wellington Management Group LLP Has $1.38 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Wellington Management Group LLP lifted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 46.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 69,813 shares of the company's stock after buying an additional 22,096 shares during the period. Wellington Management Group LLP owned about 0.10% of Kiniksa Pharmaceuticals worth $1,381,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $158,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after purchasing an additional 1,004 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after purchasing an additional 719 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $258,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at $354,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock traded down $0.32 during trading hours on Friday, hitting $20.21. 529,238 shares of the stock were exchanged, compared to its average volume of 462,946. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The business's 50-day moving average is $21.05 and its two-hundred day moving average is $21.49. The stock has a market capitalization of $1.47 billion, a P/E ratio of -144.35 and a beta of 0.31.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter last year, the company earned $0.35 earnings per share. The firm's revenue was up 46.9% on a year-over-year basis. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the subject of a number of analyst reports. Wedbush reaffirmed an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Wednesday. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $37.17.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Michael R. Megna sold 9,051 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total transaction of $203,194.95. Following the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. This trade represents a 25.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,766 shares of company stock worth $2,002,135. Insiders own 54.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.